Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Tale Of Two Healthcare Tech Firms: One Seeks Public Debut Another Looks For Buyer

Published 23/08/2023, 20:09
© Reuters.  Tale Of Two Healthcare Tech Firms: One Seeks Public Debut Another Looks For Buyer
IXIC
-
NXGN
-

Benzinga - by Vandana Singh, Benzinga Editor. NextGen Healthcare Inc (NASDAQ: NXGN), a provider of software solutions to manage patients' records, is reportedly exploring various strategic options, including the possibility of a company sale.

With a market value of $1.1 billion, NextGen Healthcare is known for its lack of a traditional headquarters due to its remote work culture.

It has hired investment bank Morgan Stanley to advise it on its discussions with potential buyers, Reuters noted, citing sources familiar with the matter.

However, the report adds that no firm agreements have been reached.

The decision to explore a potential sale comes when the healthcare sector is experiencing a surge in dealmaking. Companies in the industry are strategically seeking ways to achieve scale and cost savings, while private equity firms view healthcare as a resilient sector even in the face of looming economic uncertainties.

Healthcare deals worldwide totaled an impressive $187.8 billion in the first half of 2023, marking a significant 43% Y/Y.

Waystar, a key rival to NextGen Healthcare and owned by a private equity firm, is reportedly preparing for an initial public offering with a valuation as high as $8 billion.

However, NextGen Healthcare has faced its share of challenges. The company's shares experienced a 9% year-to-date decline, significantly underperforming the 32% rise in the Nasdaq Composite Index. This underperformance is attributed to some clients scaling back their information technology spending and the company grappling with the aftermath of a federal investigation.

In July, NextGen Healthcare agreed to pay $31 million to resolve allegations that NextGen violated the False Claims Act (FCA) by misrepresenting the capabilities of certain versions of its EHR software and providing unlawful remuneration to its users to induce them to recommend NextGen's software.

For FY23, the company reported revenue of $653.2 million, up 9.5% Y/Y, with almost 90% in recurring revenues, and expects FY24 sales of $712 million-$722 million versus consensus of $717.95 million.

Price Action: NXGN shares are up 6.63% at $17.44 on the last check Wednesday.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.